Status:

COMPLETED

Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease

Lead Sponsor:

JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Collaborating Sponsors:

Pfizer

Conditions:

Alzheimer's Disease

Eligibility:

All Genders

50-89 years

Phase:

PHASE2

Brief Summary

This study in individuals with mild to moderate Alzheimer's Disease is designed to assess:(1) safety and tolerability (2) the capacity of subcutaneous bapineuzumab to reduce brain amyloid load as meas...

Eligibility Criteria

Inclusion

  • Diagnosis of probable AD
  • Age from 50 to less than 89
  • Mini-Mental Status Exam score of 18-26 inclusive
  • Brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of AD
  • Stable doses of medications (cholinesterase inhibitors and memantine allowed)
  • Caregiver able to attend all clinic visits with patient
  • Amyloid burden on screening PET scan consistent with diagnosis of AD

Exclusion

  • Significant neurological disease other than AD
  • Major psychiatric disorder
  • Significant systemic illness
  • History of stroke or seizure, autoimmune disease, myocardial infarction within the last 2 years
  • Smoking greater than 20 cigarettes per day
  • Anticonvulsants, anti-Parkinson's, anticoagulant, or narcotic medications
  • Prior treatment experimental immunotherapeutics or vaccines for AD
  • Women of childbearing potential
  • Presence of pacemakers, CSF shunts, or foreign metal objects in the eyes, skin or body

Key Trial Info

Start Date :

December 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2013

Estimated Enrollment :

146 Patients enrolled

Trial Details

Trial ID

NCT01254773

Start Date

December 1 2010

End Date

March 1 2013

Last Update

May 9 2014

Active Locations (28)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 7 (28 locations)

1

Janssen AI Investigational Site

Tucson, Arizona, United States, 85724

2

Janssen AI Investigational Site

Tucson, Arizona, United States, 85741

3

Janssen AI Investigational Site

La Habra, California, United States, 90631

4

Janssen AI Investigational Site

Lomita, California, United States, 90277

Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease | DecenTrialz